[HTML][HTML] PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
[HTML][HTML] PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
JM Kelm, DS Pandey, E Malin… - Molecular …, 2023 - molecular-cancer.biomedcentral …
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.
JM Kelm, DS Pandey, E Malin, H Kansou… - Molecular …, 2023 - search.ebscohost.com
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
[引用][C] PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
JM Kelm, DS Pandey, E Malin, H Kansou, S Arora… - europepmc.org
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
PROTAC ing oncoproteins: targeted protein degradation for cancer therapy
JM Kelm, DS Pandey, E Malin, H Kansou, S Arora… - 2023 - kr.cup.edu.in
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
JM Kelm, DS Pandey, E Malin, H Kansou… - Molecular …, 2023 - search.proquest.com
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
JM Kelm, DS Pandey, E Malin, H Kansou… - Molecular …, 2023 - pubmed.ncbi.nlm.nih.gov
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
[HTML][HTML] PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
JM Kelm, DS Pandey, E Malin, H Kansou… - Molecular …, 2023 - ncbi.nlm.nih.gov
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
[PDF][PDF] PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
JM Kelm, DS Pandey, E Malin, H Kansou, S Arora… - molecular-cancer.biomedcentral …
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …